SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 4)
BIOSEARCH MEDICAL PRODUCTS INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
90660
(CUSIP Number)
<TABLE>
<S> <C>
Steven N. Bronson With a Linda C. Frazier, Esquire
Barber & Bronson Incorporated copy to: Broad and Cassel
201 South Biscayne Blvd., Suite 2950 201 S. Biscayne Boulevard, Suite 3000
Miami, Florida 33131 Miami, Florida 33131
(305) 536-8500 (305) 373-9400
- ------------------------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
</TABLE>
MAY 29, 1997
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
statement because of Rule 13d-1(b)(3) or (4), check the following box: [ ]
<PAGE>
SCHEDULE 13D
- --------------- -----------------
CUSIP NO. 90660 PAGE 2 OF 3 PAGES
- --------------- -----------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Steven N. Bronson
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b)[ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
PF
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
[ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OF PLACE OF ORGANIZATION
USA
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 284,494
SHARES -------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY
EACH -0-
REPORTING -------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH
284,494
-------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
284,494
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [X]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.91%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Page 3 of 3 Pages
Except as expressly amended below, the Schedule 13D, dated October 17,
1995, as amended, as filed on behalf of Steven N. Bronson with respect to the
shares of Common Stock (the "Shares"), of Biosearch Medical Products Inc., a New
Jersey corporation (the "Issuer"), remains in full force and effect.
Item 5. is hereby amended in its entirety and restated to read as
follows:
Item 5. INTEREST IN SECURITIES OF THE ISSUER.
(a)(b) Mr. Bronson may be deemed to beneficially own an
aggregate of 284,494 Shares, representing approximately 12.91% of the total
Shares of the Issuer's Common Stock outstanding. All 284,494 of such Shares are
owned of record by Mr. Bronson and with respect to which Mr. Bronson may be
deemed to have sole voting and dispositive power.
The foregoing Shares do not include any Shares held of record in the
trading account of the Company and, with respect to which Shares, the foregoing
persons disclaim beneficial ownership.
(c) On May 29, 1997, the date of the event which required the
filing of this Amendment to Schedule 13D, Mr. Bronson acquired in the open
market an aggregate of 45,000 Shares for a purchase price of $.109375 per Share.
No other transactions were effectuated in the Shares by Steven N. Bronson during
the preceding 60 days which have not previously been reported.
(d) No other person is known to have the right to receive or
the power to direct the receipt of dividends from, or the proceeds from the sale
of such securities of the Issuer.
(e) Not applicable.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information as set forth in this statement is true, complete
and correct.
Date: June 10, 1997 /S/STEVEN N. BRONSON
--------------------
Steven N. Bronson
